Lead: A peer-reviewed review published in The Lancet on Jan. 16, 2026, found no evidence that maternal acetaminophen use during pregnancy produces a clinically important increase in autism, attention-deficit/hyperactivity disorder (A.D.H.D.) or intellectual disability in children. The analysis pooled results from 43 separate studies and was led by Dr. Asma Khalil of St. George’s Hospital, University of London. Researchers concluded that acetaminophen (the active ingredient in Tylenol) should remain a first-line option for treating fever and pain in pregnancy when clinically indicated. The report was updated Jan. 17, 2026 to correct editorial details.
Key Takeaways
- The review evaluated 43 studies and reported no clinically important increase in risk for autism, A.D.H.D. or intellectual disability associated with prenatal acetaminophen exposure.
- Lead author Dr. Asma Khalil and co-authors published the synthesis in The Lancet on Jan. 16, 2026, with an editorial update on Jan. 17, 2026.
- Authors and professional bodies continue to advise judicious acetaminophen use; untreated maternal fever and severe pain carry documented risks to fetus and mother.
- Previous primary studies produced mixed findings; some reported small statistical associations while others found none, a pattern the review attributes largely to study design differences and confounding.
- The review does not establish a biological causal pathway linking typical therapeutic acetaminophen use in pregnancy to neurodevelopmental disorders.
- High-quality randomized trials on this question are not feasible for ethical reasons; conclusions rely on observational data synthesis and bias assessment.
- The report reinforces that clinical guidance should balance symptom control in pregnancy with judicious medication use and clinician judgment.
Background
Research into prenatal exposures and child neurodevelopment has expanded over decades, producing both large cohort studies and smaller case-control analyses. Acetaminophen emerged as a potential signal in several observational studies that reported modestly elevated risks for outcomes such as autism spectrum disorder and attention problems, sparking debate among clinicians and researchers. Observational signals are vulnerable to confounding by indication (mother’s underlying illness), measurement error in exposure timing or dose, and differing outcome definitions across cohorts.
Because randomized controlled trials assigning pregnant people to medication or placebo would raise ethical concerns, investigators rely on carefully designed observational methods, including sibling comparisons, dose–response analyses and statistical adjustment for maternal factors. Professional groups including the American College of Obstetricians and Gynecologists have long advised treating fever in pregnancy when clinically necessary, because high maternal fever has known associations with adverse pregnancy outcomes. That context framed calls for a systematic review of the acetaminophen literature.
Main Event
The Lancet review, led by Dr. Asma Khalil of St. George’s Hospital, pooled and critically appraised 43 published studies examining maternal acetaminophen use and later child neurodevelopment. Investigators applied prespecified criteria to assess study quality, potential confounding, exposure measurement and outcome ascertainment. Across the body of evidence, the team judged that apparent associations were small and inconsistent and that residual bias could explain many positive findings.
At a Jan. 16 news briefing, Dr. Khalil summarized the study’s central finding: the pooled evidence did not indicate a clinically important increase in risks of autism, A.D.H.D. or intellectual disability from acetaminophen used for typical indications in pregnancy. The authors emphasized that their recommendation was conditional on judicious use—using the lowest effective dose for the shortest necessary duration and consulting clinicians about fever or significant pain in pregnancy.
The review also noted heterogeneity among cohorts: some large registry-based studies and prospective birth cohorts reported small associations, while other robustly adjusted analyses and sibling-comparison designs did not. The authors highlighted exposure misclassification (timing, dose recall), confounding by indication and variable diagnostic criteria across studies as major limitations that reduce confidence in a causal interpretation.
Analysis & Implications
The review’s conclusion that no clinically important risk was identifiable shifts the balance away from alarm based on earlier mixed findings. For clinicians, the immediate implication is reaffirmation of existing guidance: treat maternal fever and disabling pain when necessary, because those maternal conditions themselves pose risks to pregnancy and fetal development. This review supports a risk-benefit approach rather than wholesale avoidance of acetaminophen in pregnancy.
For researchers and policymakers, the report underscores the difficulty of inferring causation from observational data in perinatal epidemiology. Small reported effect sizes in some studies can be driven by uncontrolled confounding or bias; distinguishing these from a true causal effect requires triangulation across methods, improved exposure measurement and careful accounting for parental and pregnancy factors.
Public communication matters: the review offers evidence to counter unverified claims that single out acetaminophen as a principal driver of rising autism prevalence. At the same time, it does not close the door on further research into rare or high-dose exposures, or on biological mechanisms that remain incompletely understood. Clinicians should continue documenting medication use and discussing risks and benefits with pregnant patients.
Comparison & Data
| Metric | Number |
|---|---|
| Reviewed studies | 43 |
| Publication date (review) | Jan. 16, 2026 (updated Jan. 17, 2026) |
| Primary outcomes assessed | Autism, A.D.H.D., intellectual disability |
The tabulated counts above reflect the review’s scope. The body of evidence included registry analyses, cohort studies and case-control reports; effect estimates varied by study design and adjustment strategy. Authors used bias-sensitivity analyses to probe how much uncontrolled confounding would be needed to generate the observed associations in earlier positive reports.
Reactions & Quotes
“We found no clinically important increase in the risk of autism, A.D.H.D. or intellectual disability.”
Dr. Asma Khalil, St. George’s Hospital (lead author)
Dr. Khalil framed the finding as a synthesis of imperfect but informative observational data and recommended continued, measured use of acetaminophen when clinically indicated.
“Physicians advise pregnant patients to use acetaminophen judiciously and to treat fever, because uncontrolled fever can harm mother and fetus.”
American College of Obstetricians and Gynecologists (professional guidance)
Professional organizations reiterated that guidance in public responses to earlier public claims linking acetaminophen and autism, stressing that clinical judgment should guide treatment of fever and severe pain in pregnancy.
“Tough it out” and “fight like hell” not to take Tylenol,
Former President (public remarks, Sept. 2025)
Those remarks, and related campaigning by public figures focusing attention on acetaminophen, helped prompt clearer synthesis of the evidence. Medical groups quickly published context and cautions in response.
Unconfirmed
- No high-quality evidence from randomized trials can confirm or refute rare causal effects of acetaminophen in pregnancy; statements about definitive causation remain unproven.
- Mechanistic pathways that would directly link typical therapeutic acetaminophen doses in pregnancy to autism have not been demonstrated and remain hypothetical.
- Some small observational findings of elevated risk may reflect residual confounding by maternal illness, genetics or socioeconomic factors rather than a drug effect.
Bottom Line
The Lancet review of 43 studies published Jan. 16, 2026 found no clinically important association between routine prenatal acetaminophen use and autism, A.D.H.D. or intellectual disability. Clinicians and professional bodies should continue to advise judicious use of acetaminophen in pregnancy while treating fever and disabling pain when needed.
For parents and pregnant patients, the evidence supports informed, case-by-case discussions with obstetric providers rather than categorical avoidance of acetaminophen. Researchers should prioritize improved exposure measurement, method triangulation and reporting transparency to further narrow remaining uncertainty.
Sources
- The New York Times (news report summarizing the Lancet review)
- The Lancet (peer-reviewed medical journal — original review published Jan. 16, 2026)
- American College of Obstetricians and Gynecologists (ACOG) (professional organization guidance and public statements)
- St. George’s Hospital / University of London (academic/clinical institution; lead author affiliation)